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Abstract
Background:  The  goal  directed  hemodynamic  therapy  is  an  approach  focused  on  the  use  of
cardiac output  and  related  parameters  as  end-points  for  fluids  and  drugs  to  optimize  tissue
perfusion  and  oxygen  delivery.  Primary  aim:  To  determine  the  effects  of  intraoperative  goal
directed  hemodynamic  therapy  on  postoperative  complications  rates.
Methods: A  meta-analysis  was  carried  out  of  the  effects  of  goal  directed  hemodynamic  ther-
apy in  adult  noncardiac  surgery  on  postoperative  complications  and  mortality  using  Preferred
Reporting  Items  for  Systematic  Reviews  and  Meta-Analyses  methodology.  A  systematic  search
was  performed  in  Medline  PubMed,  Embase,  and  the  Cochrane  Library  (last  update,  October
2014).  Inclusion  criteria  were  randomized  clinical  trials  in  which  intraoperative  goal  directed
hemodynamic  therapy  was  compared  to  conventional  fluid  management  in  noncardiac  surgery.
Exclusion  criteria  were  trauma  and  pediatric  surgery  studies  and  that  using  pulmonary  artery
catheter.  End-points  were  postoperative  complications  (primary)  and  mortality  (secondary).
he  entry  criteria  were  examined  in  full  and  subjected  to  quantifiable
up  analysis  (stratified  by  type  of  monitor,  therapy,  and  hemodynamic
tivity  analysis.Those  studies  that  fulfilled  t
analysis,  predefined  subgro
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Results:  51  RCTs  were  initially  identified,  24  fulfilling  the  inclusion  criteria.  5  randomized  clin-
ical  trials  were  added  by  manual  search,  resulting  in  29  randomized  clinical  trials  in  the  final
analysis,  including  2654  patients.  A  significant  reduction  in  complications  for  goal  directed
hemodynamic  therapy  was  observed  (RR:  0.70,  95%  CI:  0.62--0.79,  p  <  0.001).  No  significant
decrease in  mortality  was  achieved  (RR:  0.76,  95%  CI:  0.45--1.28,  p  =  0.30).  Quality  sensitive
analyses  confirmed  the  main  overall  results.
Conclusions:  Intraoperative  goal  directed  hemodynamic  therapy  with  minimally  invasive  mon-
itoring decreases  postoperative  complications  in  noncardiac  surgery,  although  it  was  not  able
to  show  a  significant  decrease  in  mortality  rate.
©  2015  Sociedade  Brasileira  de  Anestesiologia.  Published  by  Elsevier  Editora  Ltda.  This  is  an
open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Terapia  hemodinâmica  alvo-dirigida  no  intraoperatório  de  cirurgia  não  cardíaca:
revisão  sistemática  e  meta-análise
Resumo
Justificativa:  A  terapia  hemodinâmica  alvo-dirigida  (THAD)  é  uma  abordagem  focada  no  uso  do
débito  cardíaco  (DC)  e  parâmetros  relacionados,  como  desfechos  para  fluidos  e  medicamentos
para  otimizar  a  perfusão  tecidual  e  o  fornecimento  de  oxigênio.  Objetivo  primário:  determinar
os  efeitos  da  THAD  sobre  as  taxas  de  complicac¸ões  no  pós-operatório.
Métodos:  Meta-análise  dos  efeitos  da  THAD  em  cirurgias  não  cardíacas  de  adultos  sobre  as
complicac¸ões pós-operatórias  e  mortalidade,  usando  a  metodologia  PRISMA.  Uma  busca  sis-
temática  foi  realizada  no  Medline  PubMed,  Embase  e  Biblioteca  Cochrane  (última  atualizac¸ão,
outubro  de  2014).  Os  critérios  de  inclusão  foram  estudos  clínicos  randômicos  (ECRs)  nos
quais  a  THAD  no  intraoperatório  foi  comparada  com  a  terapia  convencional  de  reposic¸ão  de
líquidos  em  cirurgia  não  cardíaca.  Os  critérios  de  exclusão  foram  traumatismo  e  estudos  de
cirurgia  pediátrica  e  aqueles  usando  cateter  de  artéria  pulmonar.  Os  desfechos,  primário  e
secundário,  foram  complicac¸ões  pós-operatórias  e  mortalidade,  respectivamente.  Os  estudos
que  atenderam  aos  critérios  de  inclusão  foram  examinados  na  íntegra  e  submetidos  à  análise
quantitativa,  análise  de  subgrupo  pré-definido  (estratificada  por  tipo  de  monitor,  terapia  e
objetivo  hemodinâmico)  e  análise  de  sensibilidade  pré-definida.
Resultados:  51  ECRs  foram  identificados  inicialmente,  24  atenderam  aos  critérios  de  inclusão.
Cinco ECRs  foram  adicionados  por  busca  manual,  resultando  em  29  ECRs  para  análise  final,
incluindo  2.654  pacientes.  Uma  reduc¸ão  significativa  das  complicac¸ões  para  a  THAD  (RR:  0,70,
IC  de  95%:  0,62-0,79,  p  <  0,001).  Nenhuma  diminuic¸ão  significativa  na  mortalidade  foi  observada
(RR:  0,76,  IC  de  95%:  0,45-1,28,  p  =  0,30).  Análises  de  sensibilidade  qualitativa  confirmaram  os
principais  resultados  gerais.
Conclusões: THAD  no  intraoperatório  com  monitorac¸ão  minimamente  invasiva  diminui  as
complicac¸ões no  pós-operatório  de  cirurgia  não  cardíaca,  embora  não  tenha  mostrado  uma
reduc¸ão  significativa  da  taxa  de  mortalidade.
©  2015  Sociedade  Brasileira  de  Anestesiologia.  Publicado  por  Elsevier  Editora  Ltda.  Este e´  um
artigo  Open  Access  sob  uma  licenc¸a CC  BY-NC-ND  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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he  perioperative  management  of  high-risk  surgical  patients
ontinues to  be  a  challenge  for  the  anesthesiologists.
espite advances  in  perioperative  management,  the  inci-
ence of  serious  complications  after  major  surgery  remains
igh.1,2 A  decrease  in  perioperative  oxygen  transport  is
losely related  to  the  development  of  organ  failure  and
eath.3 It  has  also  been  demonstrated  that  a  large  high-risk
urgical population  accounts  for  12.5%  of  surgical  proce-
ures and  for  more  than  80%  of  deaths.4 Surgical  patients
a
o
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can  be  classified  as  high  risk  based  on  surgical  factors  or
atient-related factors.5 Goal  directed  hemodynamic  ther-
py (GDHT)  is  based  on  the  optimization  of  preload  with  the
se of  algorithms  based  on  fluids,  inotropes  and/or  vasopres-
ors to  achieve  a  certain  goal  in  stroke  volume  (SV),  cardiac
ndex (CI),  or  oxygen  delivery  (DO2).  The  ultimate  goal  of  this
ptimization is  to  avoid  fluid  overload,  tissue  hypoperfusion,
6nd hypoxia. All  the  studies  of  perioperative  hemodynamic
ptimization had  the  same  starting  point,  fluid  loading,
nd the  same  endpoint,  achieving  adequate  DO2.  However,
linical heterogeneity  between  studies  of  GDHT  cannot  be
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SGoal  directed  hemodynamic  therapy  
ignored,  with  regard  to  type  of  surgery,  patient’s  character-
istics, therapeutic  goals,  methods  for  achieving  these  goals
and monitoring.  The  pulmonary  arterial  catheter  (PAC)  has
been  considered  to  be  the  ‘‘gold  standard’’  for  monitor-
ing preload,  afterload,  contractility,  and  tissue  oxygenation.
The invasiveness  and  high  rate  of  complications  associated
with this  device  render  it  as  unsuitable  for  routine  use  in
most cases.  The  use  of  minimally  invasive  monitoring  has
gained popularity  in  the  past  few  years;  these  devices  have
been validated  intraoperatively.  Currently  PAC  is  not  rec-
ommended in  most  surgeries,  and  for  this  reason  it  was  not
analyzed in  this  meta-analysis.  There  are  no  data  to  support
the practice  of  using  central  venous  pressure  to  guide  fluid
therapy,7 therefore,  central  venous  pressure-guided  fluid
therapy was  not  included  in  analysis.
Yet  there  are  no  studies  in  which  different  algorithms
or different  objectives  are  compared.  The  best  method  for
assessing tissue  oxygenation  and  intravascular  volume  has
not  yet  been  defined.  The  present  review  was  designed  to
update the  published  evidence  and  determine  the  effective-
ness of  intraoperative  GDHT  with  regard  to  complications
and mortality  with  different  types  of  algorithms  and  moni-
tors used.
Material and methods
Selection  criteria
The  Preferred  Reporting  Items  for  Systematic  Reviews  and
Meta-Analyses (PRISMA)  methodology8 was  used  to  identify
the studies,  based  on  the  following  inclusion  criteria:
1.  Participants:  Adult  patients  (over  18  years)  undergoing
elective noncardiac  surgery  were  included.  The  studies
were  not  limited  in  terms  of  surgical  risk.
2. Types  of  intervention:  Intraoperative  goal  directed
hemodynamic therapy:  defined  as  hemodynamic  moni-
toring  that  allows  to  perform  a  hemodynamic  optimiza-
tion  algorithm  based  on  the  use  of  fluids,  inotropes
and/or vasopressors  to  achieve  normal  or  supranormal
hemodynamic values.  GDHT  guided  by  pulmonary  artery
catheter,  transesophageal  echocardiography  or  central
venous  pressure-guided  GDHT  were  excluded.
3. Types  of  comparison:  The  studies  that  were  selected
for  analysis  included  those  that  compared  GDHT  with
conventional  fluid  management  (monitoring  of  blood
pressure,  electrocardiogram,  heart  rate,  urine  output
and/or  central  venous  pressure).
4. Results:  RCTs  reporting  any  of  the  following  outcomes:
postoperative  complications  and/or  mortality.
5. Types  of  studies:  RCTs  where  intraoperative  GDHT  was
performed  in  adult  patients  scheduled  for  noncardiac
major surgery.  Only  peer-reviewed  manuscripts  were
included.
Sources  of  informationFollowing  the  PRISMA  protocol8 different  search  strategies
(last updated  in  October  2014)  were  used  to  iden-
tify relevant  studies  that  met  inclusion  criteria  using
EMBASE, MEDLINE  and  the  Cochrane  Library.  There  were  no
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estrictions  on  the  publication  date  or  language.  In  addi-
ion to  electronic  searching,  industry  representatives  were
ontacted  for  additional  material.  All  identified  review  arti-
les and  evidence-based  guidelines  were  hand-searched  for
dditional references.
earch items
he search  was  conducted  using  the  following  key  words:
urgery, fluid,  goal  directed,  end  point,  hemodynamic,  tar-
et, goal  and  randomized  controlled  trial.
tudy  selection  and  data  extraction
wo  independent  investigators  assessed  each  title  and
bstract in  order  to  discard  any  irrelevant  RCTs  and  identify
hose potentially  relevant.  These  RCTs  were  analyzed  select-
ng those  that  met  the  inclusion  criteria  outlined  above.
CT data  extraction  was  performed  by  two  different  inves-
igators and  any  discrepancy  required  further  analysis  and
onfirmation by  a  third  investigator.  The  authors  reviewed
he data  analysis  in  order  to  avoid  errors  in  data  transcrip-
ion.
ssessment  of  risk  of  bias  in  included  studies
ias  assessment  risk  was  performed  using  the  Cochrane  risk
f bias  tool.  From  this  tool,  we  used  seven  domains  to  assess
he methodological  quality  of  the  studies  included  in  the
nalysis.
utcome variables
he primary  outcome  was  the  overall  postoperative
omplications.  The  results  were  stratified  according  to  the
ollowing variables:  monitor  utilized,  therapy  used  to  reach
 hemodynamic  goal  and  the  hemodynamic  goal.  For  the
redefined subgroup  analysis,  studies  were  grouped:
1)  Monitor:  (a)  Arterial  pulse  contour  analysis  methods
(Vigileo/Flotrac®,  Edwards  Lifesciences  Corporation,
USA;  ProAQT®,  Pulsion  medical  systems  SE,  Germany;
LiDCO Plus®, LiDCO  Ltd.,  UK);  (b)  oesophageal  Doppler
Monitoring-ODM (CardioQ®, Deltex  Medical,  UK);  (c)
noninvasive  methods  (Masimo®, Masimo  Corporation;
CNAP® PPV,  CNSystems  Medizintechnik  AG)  and  (d)
measures  of  oxygen  delivery  and  extraction  methods.
2) Therapy:  (a)  Fluids;  (b)  fluids  and  inotropes;  (c)
vasopressors and  fluids  and  (4)  fluids,  inotropes  and
vasopressors.
3)  Hemodynamic  goals:  (a)  SV  maximization;  (b)
CI  >  2.5  mL/min/m2;  (c)  preload  responsiveness  (includ-
ing  stroke  volume  variation,  Pulse  pressure  variation
and Pleth  Variability  Index®)  and  (d)  ScvO2.
The  secondary  outcome  was  mortality.
tatistical  analysiseview  manager  (‘‘Revman’’)  10  for  MAC  (Cochrane  col-
aboration, Oxford,  UK)  was  used  for  statistical  analysis.
eta-analysis was  carried  out  using  the  Mantel--Haenszel
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lFigure  1  Flow  diagram
andom-effects  model,  with  results  presented  as  risk  ratio
RR) with  a  95%  confidence  interval  (CI).  Forest  plots
ere then  constructed,  considering  p  <  0.050  as  statistically
ignificant effect.  Statistical  heterogeneity  was  evaluated
sing I2 statistics;  I2 values  of  less  than  25%  were  defined
s low  heterogeneity,  25--50%  as  moderate  heterogeneity
nd greater  than  50%  as  high  heterogeneity.  A  2 test  for
c
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igure  2  Review  authors’  judgements  about  each  risk  of  bias  item
ow  risk  of  bias;  white,  unclear  risk  of  bias;  red,  high  risk  of  bias.strating  search  strategy.
eterogeneity  was  performed,  with  p  <  0.100  regarded  as
tatistically significant.  A  priori  sensitivity  analyses  were
onducted on  both  the  primary  and  the  secondary  out-
omes by  restricting  the  analysis  to  high  quality  trials:  to
hose studies  that  showed  no  allocation  bias  and  those
ithout randomization/allocation  bias.  Publication  bias  was
ssessed using  funnel  plot  techniques.
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Figure  3  Review  authors’  judgements  about  each  risk  of  bias
item for  each  included  study.Goal  directed  hemodynamic  therapy  
Results
Study  selection
There  were  14,160  references  in  electronic  databases,  of
which 1003  were  screened.  Of  those,  55  RCTs  were  analyzed
and 24  of  them  were  included  for  systematic  review  and
meta-analysis, excluding  those  who  did  not  meet  the  inclu-
sion criteria.  Finally  a  total  of  29  RCTs  were  included9--37;
5 RCTs  were  added  by  manual  search.  2654  patients  were
included. Fig.  1 shows  the  flowchart  used  for  item  selection.
Assessment  of  risk  of  bias  in  individual  studies
Bias  risk  was  analyzed  with  the  Cochrane  tool.  This  was  per-
formed by  two  authors  independently  and  we  resolved  any
disparity by  discussion  and  the  involvement  of  a  third  per-
son. We  present  the  methodological  quality  in  a  summary
table and  a  graph  (Figs.  2  and  3).
Characteristics  of  the  studies  included  in  the
analysis
The  selected  articles  describe  the  results  of  RCTs  that  eval-
uated the  use  of  intraoperative  GDHT  in  noncardiac  elective
surgery, and  that  included  postoperative  complications
and/or mortality  as  outcome.  The  characteristics  of  the
included RCTs  are  shown  in  Table  1.
Primary  results
1.  Total  complications
Analyzing  the  29  RCTs,  26  describe  the  total  associated
complications10--37 GDHT  was  associated  with  a  significant
reduction  in  overall  complication  compared  with  patients
treated  in  the  control  group  (RR:  0.70,  95%  CI:  0.62--0.79,
p <  0.001)  (Fig.  4).
2. Complications  by  monitor
A significant  decrease  in  complications  was  found  in
subgroup  based  on  pulse  contour  analysis  (RR:  0.78,  95%
CI:  0.59--0.99,  p  =  0.04)  and  subgroup  ODM  (RR:  0.67,  95%
CI:  0.53--0.85,  p  <  0.001).  However,  it  was  not  shown  in
the  subgroup  of  noninvasive  monitoring  (RR:  0.57,  95%
CI:  0.28--1.15,  p  =  0.12)  and  was  based  on  measures  of
oxygen  delivery  and  extraction  methods  (RR:  0.59,  95%
CI:  0.20--1.80,  p  =  0.36)  (Fig.  5).
3. Complications  by  hemodynamic  therapy
A significant  decrease  in  complications  was  observed
in the  fluids  as  monotherapy  subgroup  (RR:  0.69,  95%
CI:  0.57--0.84,  p  <  0.001),  fluids  and  vasopressors  sub-
group  (RR:  0.76,  95%  CI:  0.68--0.85,  p  <  0.001),  and  fluids,
vasopressors  and  inotropes  subgroup  (RR:  0.54,  95%  CI:
0.32--0.89,  p  =  0.02).  However,  the  use  of  fluids  and
inotropes showed  no  decrease  in  complications  (RR.  0.66,
95%  CI:  0.34--1.28,  p  =  0.22)  (Fig.  6).
4. Complications  by  hemodynamic  goal
A decrease  in  complications  was  associated  with  the
use  of  GDHT  in  the  following  subgroups:  Svmaximization
(RR: 0.73,  95%  CI:  0.61--0.89,  p  <  0.001),  in  the  subgroup
preload  responsiveness  (RR:  0.73,  95%  CI:  0.59--0.95),
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Table  1  PICO  characteristic  of  included  studies.
Study  Year  Patients  Intervention  Comparator  Outcomes  Study
design
Sinclair
et  al.
1997  Patients  over  55
years undergoing
hip replacement
surgery
CardioQ-guided  GDHT
by optimizing  SV  and
cFT with  fluids
n 20
Standard  care
n 20
Length of  stay,
hemodynamic
parameters
RCT
Conway
et al.
2002  ASA  I--III  patients
undergoing
colorectal  surgery
CardioQ-guided  GDHT
by optimizing  SV  with
fluids
n 29
Standard  care
n 28
Hemodynamic
parameters, bowel
function
parameters,
complications
RCT
Gan et  al.  2002  ASA  I--III  patients
undergoing  major
surgery
CardioQ-guided  GDHT
by optimizing  SV  with
fluids
n 50
Standard  care
n 50
Length of  stay,
complications
RCT
Venn
et al.
2002  Patients  undergoing
hip replacement
surgery
CardioQ-guided  GDHT
by optimizing  SV  with
fluids
n 30
Standard  care
n 29
Length of  stay,
hemodynamic
parameters
RCT
Walkeling
et al.
2005  ASA  I--III  patients
undergoing
colorectal  surgery  in
an  ERAS  protocol
CardioQ-guided  GDHT
by optimizing  SV  with
fluids
n 64
Standard  care
(CVP
12--15 mmHg)
n  64
Length of  stay,
oral tolerance,
complications,
quality  of  recovery
RCT
Nobblet
et  al.
2006  Patients  undergoing
colorectal  surgery
CardioQ-guided  GDHT
by optimizing  SV  with
fluids
n 54
Standard  care
n 54
Length of  stay,
complications,
bowel function
recovery
RCT
Donati
et al.
2007  High-risk  patients
undergoing  major
abdominal surgery
GDHT  by  optimizing
ERO2 with  fluids  and
inotropes
n 68
Standard  care
n 67
Hemodynamic
parameters,
complications,
length of  stay
RCT
Lopes
et al.
2007  High-risk  patients
undergoing  major
abdominal surgery
CNAP-guided  GDHT
by optimizing
PP  <  10%
n 17
Standard  care
n 16
Hemodynamic
parameters,
complications, ICU
stay, length  of  stay
RCT
Buettner
et  al.
2008  ASA  I--III  patients
undergoing  major
abdominal surgery
(general,
gynecological)
PPV-guided  GTHD
with fluids  and
vasopressors
n 40
Standard  care
n 40
Tissue oxygenation
parameters,
hemodynamic
parameters,
length  of  stay
RCT
Senagore
et al.
2009  Low-  and
moderate-risk
patients  undergoing
laparoscopic  bowel
resection in  an  ERAS
protocol
CardioQ-guided  GDHT
by optimizing  SV  with
fluids n  21(LR)  or  HES
6%
n 21
Standard  care
n 22
Complications,
length of  stay
RCT
Jammer
et al.
2010  Patients  undergoing
colorectal  surgery
ScvO2-guided  GDHT
with  fluids
n 121
Standard  care
n 120
Complications RCT
Van der
Linden
et al.
2010  ASA  II--III  patients
undergoing  low  limb
arterial by-pass
Flotrac-guided  GDHT
maintaining a
CI >  2.5  mL/min/m2
and  CVP  <  15  mmHg
with fluids  and
inotropes.
Sevoflurane
anesthesia
n 20
Standard  care
guided by
APm and  CVP
n 17
Hemodynamic
parameters,
Complications,
length of  stay
RCT
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Table  1  (Continued)
Study  Year  Patients  Intervention  Comparator  Outcomes  Study
design
Forget
et  al.
2010  Patients  undergoing
major abdominal
surgery
Masimo-guided  GDHT
by optimizing  PVI
with fluids  and
vasopressors
n 41
Standard  care
n 41
Amount of  fluid
administered,
lactate levels,
complications,
length of  stay,
mortality
RCT
Mayer
et al.
2010  High-risk  patients
undergoing  major
abdominal surgery
Flotrac-guided  GDHT
maintaining a
CI >  2.5  mL/min/m2
with  fluids,  inotropes
and vasopressors
n 30
Standard  care
(restrictive)
n 30
Length of  stay,
complications
RCT
Benes
et al.
2010  High-risk  patients
(ASA III--IV)
undergoing  major
abdominal surgery
Flotrac-guided  GDHT
by optimizing  SVV
with fluids  and
inotropes
n 60
Standard  care
n 60
Complications,
length of  stay,  ICU
stay, mortality
RCT
Cecconi
et al.
2011  Patients  undergoing
hip replacement.
Regional  Anesthesia
Flotrac-guided  GDHT
by optimizing  SV  and
DOI >  600  mL/min/m2
with  fluids,  inotropes
and vasopressors
n 20
Standard  care
n 20
Amount of  fluids
administered,
vasoactive  use,
complications,
length of  stay
RCT
Challand
et al.
2012  Patients  undergoing
colorectal  surgery  in
an  ERAS  protocol.
All patients
CardioQ-guided  GDHT
by optimizing  SV  with
fluids
n 89
Standard  care
n 90
Length of  stay,
readmission,
complications
RCT
Brandstrup
et al.
2012  ASA  I--III  patients
undergoing
colorectal  surgery
CardioQ-guided  GDHT
by optimizing  SV  with
fluids
n 71
Standard
care.  Zero
balance
n 79
Complications,
length of  stay
RCT
Bartha
et al.
2013  Patients  over  70
years undergoing
hip replacement  in
an ERAS  protocol
LiDCO  plus  guided
GDHT by  optimizing
SV and
DOI  >  600  mL/min/m2
with  fluids  and
inotropes
n 74
Standard  care
n 75
Complications,
amount of  fluids
administered,
hemodynamic
response, length
of stay
RCT
Zhang
et al.
2013  ASA  I--II  patients
undergoing
gastrointestinal
surgery
PPV-guided  GDHT
with fluids:  LR  n  20;
and HES  6%
n 20
Standard  care
n 20
Length of  stay,
bowel function
parameters,
complications,
hemodynamic
parameters
RCT
Salzwedel
et al.
2013  ASA  II--III  patients
undergoing  major
abdominal surgery
ProAQT-guided  GDHT
maintaining a
CI >  2.5  mL/min/m2
with  fluids,  inotropes
and vasopressors
n 79
Standard  care
n 81
Complications,
length of  stay
RCT
Scheeren
et al.
2013  ASA  III--IV
undergoing  major
abdominal surgery
Flotrac-guided  GDHT
by optimizing  SV  and
SVV with  fluids
n 26
Standard  care
n 26
Complications,
SOFA score,  ICU
stay, mortality
RCT
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Table  1  (Continued)
Study  Year  Patients  Intervention  Comparator  Outcomes  Study
design
Zhang
et  al.
2013  ASA  I--II  undergoing
lobectomy  surgery
Flotrac-guided  GDHT
by optimizing  SVV
and maintaining  a
CI >  2.5  mL/min/m2
with  fluids  and
inotropes
n 30
Standard  care
n 30
Length of  stay,
complications
RCT
Forget
et al.
2013  Low-  and
moderate-risk
patients  undergoing
colorectal  surgery  in
an  ERAS  protocol
Masimo-guided  GDHT
by optimizing  PVI
with fluids  (IPV  <  13)
n  10
Standard  care
n 11
Amount of  fluids
administered,
complications,
mortality,  length
of stay
RCT
Zakhaleva
et al.
2013  Patients  undergoing
colorectal  surgery  in
an  ERAS  protocol
CardioQ-guided  GDHT
by optimizing  SV  and
cFT with  fluids
n 32
Standard  care
n 40
Time of  surgery,
amount  of  fluids
administered,
bowel function
recovery,
complications,
length  of  stay,
mortality
RCT
Srinivasa
et al.
2013  ASA  I--III  patients
undergoing
colorectal  surgery
without an  ERAS
protocol
CardioQ-guided  GDT
by optimizing  SV  and
cFT with  fluids
n 37
Standard  care
n 37
Hemodynamic
parameters,
complications
RCT
McKenny
et al.
2013  Patients  undergoing
major gynecological
surgery
CardioQ-guided  GDHT
by optimizing  SV  and
cFT with  fluids
n 51
Standard  care
n 50
Complications,
length of  stay
RCT
Zheng
et al.
2013  Elderly  high-risk
patients  undergoing
major abdominal
surgery
Flotrac-guided  GDHT
by maintaining  a
CI >  2.5  mL/min/m2
with  fluids  and
vasopressors
n 30
Standard  care
n 30
Cardiovascular
complications,
bowel function
parameters,  ICU
stay, length  of  stay
RCT
Peng
et  al.
2014  Adult  patients
undergoing  major
orthopedic surgery
Flotrac-guided  GDHT
to maintain  SVV  <  10
or  <14%  in  prone
position
n 40
Standard  care
n 40
Splanchnic organ
functions,
postoperative
complications
RCT
GDHT, goal directed hemodynamic therapy; SV, stroke volume; Cft, corrected flow time; RCT, randomized controlled trial; ASA, American
Society of Anesthesiologist; CVP, central venous pressure; ERAS, enhanced recovery after surgery; ERO2, oxygen extraction index; PP,
increment of pulse pressure; PPV, pressure pulse variation; LR, lactate of ringer; HES, hydroxyethyl starch; CI, cardiac index; PVI, ple-
oxyge
M
N
i
S
s
N
(
(
r
cthysmography variation index; SVV, stroke volume variation; DOI, 
ScvO2, central venous oxygen saturation.
p  <  0.001),  and  with  a  CI  target,  CI  >  2.5  mL/min/m2 (RR:
0.58,  95%  CI:  0.44--0.76,  p  <  0.001),  whereas  in  the  sub-
group  that  utilized  measures  of  oxygen  delivery  and
extraction  methods  no  significant  decrease  was  observed
(Fig.  7).ortality
o  significant  differences  were  found  with  regard  to  mortal-
ty (RR:  0.76,  95%  CI:  0.45--1.28,  p  =  0.30)  (Fig.  8).
h
w
p
pn delivery index; SVI, indexed stroke volume; PP, pulse pressure;
ensitivity analysis,  assessment  risk  of  bias  across
tudies  and  publication  bias
o changes  in  the  results  with  regard  to  complications
[RR: (CI  95%)  0.71  (0.61--0.82),  p  <  0.01])  or  mortality  ([RR:
CI 95%)  0.77  (0.42--1.40),  p  =  0.39])  were  observed  when
estricting the  analysis  to  those  studies  that  had  no  allo-
ation bias;  or  when  restricting  the  analysis  to  those  that
ad no  allocation  and/or  randomization  bias  in  the  results
ith regard  to  complications  [RR  (CI  95%)  0.69  (0.59--0.81),
 < 0.01]  and  mortality  ([RR  (CI  95%)  0.95  (0.45--1.85),
 = 0.87])  On  the  other  hand,  a  prespecified  group  analysis
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has  been  conducted  and  described  above.  A  funnel  plot  was
drawn for  the  primary  outcome  comparison  to  explore  the
possibility of  publication  bias.  The  symmetry  of  the  funnel
plot was  assessed  visually  and  did  not  suggest  publication
bias (Fig.  9).
Discussion
Numerous  studies  have  reported  differences  between
technologies, especially  in  their  response  to  typical  sur-
gical interventions  such  as  fluid  and  vasoactive  drug
administration.38 The  results  obtained  with  one  type  of
monitoring cannot  be  extrapolated  to  those  obtained  with
other monitors.39 RCTs  using  noninvasive  monitors  were
limited both  in  number  of  patients  studied  and  meth-
odological quality.  How  minimal  invasive  cardiac  output
monitoring techniques  can  be  used  to  guide  individ-
ualized fluid  management40 needs  to  be  sustained  by
validation studies  that  adhere  to  the  proposed  methodologi-
cal considerations41 as  well  as  large-scale  clinical  outcome
studies.
There is  some  evidence  that  SV  maximization  strategies
could be  harmful  in  aerobically  fit  patients  by  lead-
ing to  volume  overload,25 and  recent  evidence  suggests
that this  goal  does  not  provide  the  benefits  previously
described.42
However,  the  results  of  our  meta-analysis  show  that
this hemodynamic  goal  remains  valid.  The  use  of  dynamic
t
p
s vs  control  group  on  overall  complications.
esponse  parameters  to  volume  may  decrease  the  risk  of  vol-
me overload.  A  CI  >  2.5  mL/min/m2 as  hemodynamic  target
ithin algorithms  in  which  fluids,  vasopressors  and  inotropes
re used  avoid  the  risk  of  hypotension  due  to  decreased
asomotor tone.  The  use  of  inotropes  increases  the  CO  in
ituations where  the  patient  is  nonresponsive  to  the  volume
nd does  not  present  a reduced  vasomotor  tone.  Inotropic
upport with  dobutamine  can  result  in  changes  in  microvas-
ular flow  related  to  direct  effects  on  the  microcirculation
s well  as  global  CO.43 With  the  exception  of  ScvO2,  that
as only  evaluated  in  one  RCT,19 and  was  not  associated
ith better  outcomes,  this  meta-analysis  has  not  been  able
o detect  significant  differences  between  subgroups.  There-
ore it  seems  reasonable  to  adapt  GDHT  to  risk  patient,
ype of  surgery  as  well  as  its  duration44 as  recommended
y recent  European  Society  of  Anaesthesiology  guidelines.45
 multicenter  observational  trial  in  patients  with  intra-
bdominal surgery  found  that  low  ScvO2 was  associated  with
n increased  risk  of  postoperative  complications  in  high-risk
urgery. In  this  trial,  the  optimal  value  of  mean  ScvO2 to
iscriminate between  patients  who  did  or  did  not  develop
omplications was  73%  (sensitivity  72%,  specificity  61%)46
ne  of  the  major  limitations  of  venous  oximetry  is  that,
s a  global  marker  of  demand-supply  balance,  it  does  not
eflect organ-specific  malperfusion.  Whether  ScvO2 moni-
oring improves  outcomes  in  surgical  patients  remains  to  be
roven in  large  RCTs.
Unlike our  results,  a  recent  meta-analysis  has  shown  a
ignificant benefit  of  GDHT  in  patients  receiving  fluids  and
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Figure  5  Effect  of  GDHT  in  the  protocol  group  vs  control  group  on  overall  complications  grouped  by  monitor.  Pulse  contour
d :  CN
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c
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m
l
f
ievices: Vigileo/Flotrac®,  ProAQT,  and  LiDCO  Plus®.  No  invasive
notropes  in  order  to  achieve  supraphysiological  targets  for
xygen delivery  in  high-risk  patients.47
This  meta-analysis  was  unable  to  demonstrate  a  signifi-
ant reduction  in  mortality.  There  are  a  number  of  reasons  to
xplain why  the  control  mortality  may  have  decreased  over
ime. These  include:  (1)  better  overall  care  thus  decreasing
ortality for  similar  patients;  (2)  clinicians’  awareness,
a
t
t
eAP® PPV  and  Masimo®.
earning  from  previous  early  published  studies  and  there-
ore drifting  their  practice  toward  lower  risk  groups;  (3)
mprovement in  technology,  that  has  become  less  invasive
48nd therefore,  gaining  more  credibility. Another  reason  for
his may  be  that  the  most  recent  studies  are  not  powered
o assess  mortality;  in  earlier  studies,  mortality  was  consid-
red the  most  relevant  endpoint,  but  this  has  changed  to
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patient group,  and  as  a  result,  have  very  low  or  no  mortal-
ity. However,  a  reduction  in  mortality  associated  with  GDHT
was demonstrated  in  groups  of  extremely  high-risk  patients
49(baseline mortality  rate  of  >20%) as  well  as  with  long-term
follow-up.50
Unlike  previous  meta-analysis,  we  have  not  included
those studies  in  which  PAC  was  used,  since  these  studies
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cere  published  over  10  years,  and  do  not  reflect  cur-
ent practice.  Grocott  et  al.  meta-analysis51 included  31
tudies with  5292  participants.  The  results  are  dominated
y a  single  large  RCT  with  a  weight  of  more  than  60%
52f the  overall  population  in  which  PAC  was  used. The
resent meta-analysis  confirms  that  the  use  of  minimally
nvasive monitoring  is  effective  and  reduces  postoperative
omplications. Postsurgical  complications  have  a  dramatic
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Mmpact  on  costs.  Potential  costs  savings  resulting  from
DHT are  substantial53 and  seem  to  be  cost  effective  even
ith moderate  clinical  effect.54 Particularly,  ODM  tech-
ology has  been  considered  favorably  by  both  the  NHS
enter for  evidence-based  purchasing  in  the  United  King-
om and  United  States  Agency  for  Healthcare  Research  and
uality.55,56
d
a
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tesearch  implications
ore  studies  in  which  different  types  of  monitoring  and
ifferent types  of  algorithms  and  hemodynamic  therapies
re compared  in  patients  with  different  risk  in  order  to
chieve optimal  hemodynamic  goals  are  needed.  In  addi-
ion, outcome  report  should  be  standardized.  In  this  regard,
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aFigure  8  Effect  of  GDHT  in  the  pro
recommendations  for  the  evaluation  and  standardization  of
perioperative complications  have  been  recently  published.57
In  summary,  more  studies  are  needed  to  demonstrate  a  sig-
nificant reduction  in  mortality  associated  with  GDHT.Weaknesses  in  study
The  study  by  Mayer  et  al.22 has  been  under  investigation
for ethical  reasons,  the  manuscript  has  not  been  withdrawn
0
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Figure  9  Funnel  plot  of  the  published  studies  in  relation  to
the primary  outcome.  The  measure  of  precision  used  is  the
standard error  (SE)  of  the  log  RR.
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nd  remains  part  of  the  scientific  record  at  the  time  we
earched the  literature.  To  verify  potential  biases  in  our
esults, both  the  primary  and  the  secondary  outcome  were
e-examined without  including  the  Mayer  et  al.22 manuscript
nd no  differences  were  found.
Many  trials  were  single  center  trials  and  only  one  has
nvestigated more  than  100  patients  per  group.19 Differences
n methodological  quality  may  cause  heterogeneity.  Smaller
tudies tend  to  be  conducted  and  analyzed  with  less  method-
logical rigor  than  larger  studies,  and  trials  of  lower  quality
lso tend  to  show  larger  intervention  effects.
The  major  limitation  of  our  analysis  is  that  overall
omplications were  analyzed,  regardless  of  the  severity  of
hese and  their  impact  on  length  of  stay  and/or  mortal-
ty. Furthermore,  the  use  of  different  surgical  interventions,
ifferent monitoring  systems  and  algorithms  adds  more  het-
rogeneity  to  the  analysis.  Thus,  study  heterogeneity  may
educe the  precision  of  treatment  effect  estimates  and
educe the  generalizability  of  the  results  of  this  meta-
nalysis.
The present  meta-analysis  is  based  on  studies  that
escribe the  incidence  of  postoperative  complications.  It
as to  be  recognized  that  the  reporting  of  complications  is
ot consistent  and  that  the  definitions  used  can  differ  in
ype, definition  and  importance  between  studies,  limiting
he applicability  of  some  of  our  findings.
Furthermore,  and  unlike  previous  meta-analysis,  the
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226  
omplications,  without  conducting  an  organ-specific47,58 or
tratified by  risk49 analysis.  Despite  these  limitations,  the
esults are  consistent  in  most  subgroups  analyzed  and  even
hen the  analysis  is  restricted  to  those  studies  with  higher
uality.
onclusions
he  results  of  this  meta-analysis  show  that  the  use
f intraoperative  GDHT  with  minimally  invasive  monitor-
ng decreases  postoperative  complications  in  noncardiac
urgery, although  it  was  not  possible  to  show  a  significant
ecrease in  mortality  rate.  ScvO2 monitoring  was  not  able
o decrease  the  frequency  of  complications.
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